Biotech Values

[genisi]

Chimaeric antigen receptor (CAR) therapy vs. T-cell receptor(TCR)

But there is one difficulty: the T-cell receptors must be genetically matched to the patient's immune type.
A more flexible tactic, called chimaeric antigen receptor (CAR) therapy, avoids this constraint. It uses a gene that encodes artificial, antibody-like proteins that bind the antigens studding the tumour cell's surface without needing to match the patient's immune type.

In other words, CARs work in an MHC independent manner.